GlassScriptPhysician profile
Jamie Deputy
NPI 1053851436
$4,797.01
in general payments reported to CMS, 2019-2025
20 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,488 · 2022: $1,005 · 2023: $667 · 2024: $1,422 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $943.66 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $897.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $461.36 | 2022-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $434.67 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $363.90 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $337.99 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $328.12 | 2021-2024 | Trintellix |
| Alkermes, INC. | $251.35 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.20 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $182.30 | 2023-2025 | Uzedy, Austedo Xr |
| Merck Sharp & Dohme LLC | $92.89 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $80.55 | 2023-2024 | Auvelity |
| Almatica Pharma LLC | $42.61 | 2021-2022 | |
| Indivior INC. | $41.28 | 2024 | Sublocade |
| Noven Therapeutics, LLC | $38.56 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.83 | 2025 | Cobenfy |
| Tris Pharma INC | $24.65 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.98 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.92 | 2021 | |
| Corium, LLC | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Deputy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.